Islet-on-Chip Co-Culture With Endothelium for T2D Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing rodent models for studying β-cell dysfunction and insulin resistance in Type 2 diabetes are poorly predictive of human disease mechanisms and drug efficacy, necessitating the development of human Organ-chip models that can replicate the range of defects in insulin secretion and sensitivity.
Innovation Solution
A method for generating pancreatic and endothelial cells from induced pluripotent stem cells (iPSCs) using specific growth factors and culture conditions, followed by co-culturing these cells in a microfluidic device with endothelial cells to enhance islet cell functionality, particularly insulin secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rodent models are used to study β-cell dysfunction and insulin resistance, then research can be conducted with available models, but the predictive value for human disease mechanisms and drug efficacy is poor
Solution Approach 1:
The patent creates human organ-chip models that copy and replicate human pancreatic islet cells and vascular endothelium in a controlled microfluidic environment. This allows direct modeling of human disease mechanisms without relying on rodent proxies, thereby improving predictive value while maintaining adaptability through customizable cell sources and culture conditions.
2Reliability
If human organ-chip models are developed to replicate T2D phenotypes, then drug screening relevance is improved, but the complexity of the system increases
Solution Approach 1:
The patent segments the complex human pancreas-vascular system into distinct but interconnected components: pancreatic islet cells cultured in one chamber and vascular endothelium in another, connected via porous membranes. This segmentation allows independent optimization of each cell type while maintaining physiological interactions, improving drug screening relevance without overwhelming system complexity.
Solution Approach 2:
The patent introduces porous membranes as intermediaries between islet cells and vascular endothelium, enabling controlled paracrine signaling and nutrient exchange. This intermediary structure simplifies the overall system by providing a standardized interface for cell-cell communication while maintaining the complexity needed for physiologically relevant drug screening.
3Productivity
If islet cells are co-cultured with vascular endothelium in microfluidic devices, then islet cell functionality and insulin secretion are enhanced, but the culture system becomes more complex
Solution Approach 1:
The patent employs microfluidic hydrodynamics to perfuse culture media through channels containing islet cells and vascular endothelium. This hydraulic system enables controlled delivery of nutrients, growth factors, and insulin to enhance islet cell functionality while automating the culture process, thereby improving productivity without proportionally increasing operational complexity.
Data Source
Figure 1
Figure 2
Figure 3A~3C
AI summary
Type 2 diabetes (T2D) is a clinical syndrome caused by insufficient insulin secretion for insulin requirements. described herein are compositions and methods for microphysiological MPS models of disease (MODs) for diabetes. These platforms allow one to compare the effect of chronic β-cell stimulation in the presence and absence of patient specific immune cells in IPSC-derived islets from each group. Additionally, one can reproduce the T2D β-cell phenotype, using islets-on-chips will also be exposed to gluco-lipotoxicity. Likewise, skeletal muscle-on-chips are exposed to patient specific activated immune cells, variable motor neuron innervation and lipids characteristic of T2D.